Prothena Corporation (PRTA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.31
- Estimate
- -$0.38
- Surprise
- +18.4%
- Revenue (period 2026-06-30)
- $1.0M
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
Prothena Corporation (PRTA) reported a narrower loss than forecast — diluted EPS of -$0.31 against the -$0.38 estimate (a 18.4% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRTA Sell at 5.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +18.4% surprise compares with a +79.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (1.8 < 4.0)
- Value-trap signals (2/5): Material insider selling (38 sells, 0.26% of cap), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.45
- Price target
- $18.62
- Stop
- $8.79
- Upside to target
- +97.0%
- Reward-to-risk
- 6.5:1
Risk check: RSI 70 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
PRTA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $485.1M
- P/E (fwd)
- -6.2
- 52-week range
- $7.73–$11.80
- Off 52-week high
- 19.9%
- RSI (14)
- 70
- Volume vs avg
- 0.80×
- Score today
- 5.1/10